|Posted date||Jul 4, 2013|
|International application number||2012JP062230|
|International publication number||WO 2012/153854|
|Date of international filing||May 11, 2012|
|Date of international publication||Nov 15, 2012|
The invention provides novel means for modulating the expression of cytokine-chemokine genes associated with inflammation and infection. Specifically, the invention provides an antisense nucleotide that comprises the sequence complementary to the 3'UTR of the CCL2, CCL20, CX3CL1, IL-23A, CD69, NF-?B p65, TNF-a, Fam89a, Grk5, phosopholipid scramblase 1, Runx1, semaphorin 4A, Steap4, lymphotoxin ss Psmb10 or TLR2 gene induced by IL-1ss and that is capable of modulating the expression of the gene
sense oligonucleotide that contains the sequence complementary to the endogenous antisense transcription product containing the sequence complementary to the 3'UTR of the gene and that is capable of modulating the expression of the gene
and an agent that prevents and/or treats inflammatory disease or infection and contains the sense or antisense nucleotide.
|IPC(International Patent Classification)||
Contact Information for " CYTOKINE-CHEMOKINE MODULATOR "
- Ritsumeikan University Office of Sciences and Engineering Research
- URL: http://www.ritsumei.ac.jp/eng/html/research/
- Address: 1-1-1, Nojihigashi, Kusatsu, Shiga, Japan , 525-8577
- Phone: 81-77-561-2802
- Fax: 81-77-561-2811